MARCUS DANIELS: Open Payments
NPI 1962072363 · GILBERT, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,106 in 112 payments from 18 companies in 2025. Trend: 2023 $2,371 · 2024 $1,310 · 2025 $2,106
Food & beverage: $2,106
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $454 |
| Corium, LLC | 16 | $252 |
| Supernus Pharmaceuticals, Inc. | 12 | $233 |
| Alkermes, Inc. | 7 | $217 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $161 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $134 |
| Lundbeck LLC | 4 | $94 |
| Axsome Therapeutics, Inc. | 4 | $80 |
| Vanda Pharmaceuticals Inc. | 3 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
Products named: VRAYLAR, Azstarys, Qelbree, LYBALVI, CAPLYTA, REXULTI, TRINTELLIX, Auvelity.
Industry payments across AZ — which companies pay providers there.
